These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17004125)

  • 1. Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria.
    Kshirsagar SA; Blaschke TF; Sheiner LB; Krygowski M; Acosta EP; Verotta D
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):35-55. PubMed ID: 17004125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.
    Wasmuth JC; Lambertz I; Voigt E; Vogel M; Hoffmann C; Burger D; Rockstroh JK
    Eur J Clin Pharmacol; 2007 Oct; 63(10):901-8. PubMed ID: 17690876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.
    Cressey TR; Urien S; Hirt D; Halue G; Techapornroong M; Bowonwatanuwong C; Leenasirimakul P; Treluyer JM; Jourdain G; Lallemant M;
    Ther Drug Monit; 2011 Feb; 33(1):25-31. PubMed ID: 21233689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.
    Rhame FS; Rawlins SL; Petruschke RA; Erb TA; Winchell GA; Wilson HM; Edelman JM; Abramson MA
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4200-8. PubMed ID: 15504842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-finding study of a once-daily indinavir/ritonavir regimen.
    Hugen PW; Burger DM; ter Hofstede HJ; Koopmans PP; Stek M; Hekster YA; Reiss P; Lange JM
    J Acquir Immune Defic Syndr; 2000 Nov; 25(3):236-45. PubMed ID: 11115954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children.
    Curras V; Hocht C; Mangano A; Niselman V; Mariño Hernández E; Cáceres Guido P; Mecikovsky D; Bellusci C; Bologna R; Sen L; Rubio MC; Bramuglia GF
    Pharmacology; 2009; 83(1):59-66. PubMed ID: 19052483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.
    Csajka C; Marzolini C; Fattinger K; Décosterd LA; Telenti A; Biollaz J; Buclin T
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3226-32. PubMed ID: 15328077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
    Aarnoutse RE; Wasmuth JC; Fätkenheuer G; Schneider K; Schmitz K; de Boo TM; Reiss P; Hekster YA; Burger DM; Rockstroh JK
    Antivir Ther; 2003 Aug; 8(4):309-14. PubMed ID: 14518700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
    Kappelhoff BS; Huitema AD; Sankatsing SU; Meenhorst PL; Van Gorp EC; Mulder JW; Prins JM; Beijnen JH
    Br J Clin Pharmacol; 2005 Sep; 60(3):276-86. PubMed ID: 16120066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study.
    Avihingsanon A; van der Lugt J; Singphore U; Gorowara M; Boyd M; Ananworanich J; Phanuphak P; Burger D; Ruxrungtham K
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1170-6. PubMed ID: 22250979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
    Cahn P; Vibhagool A; Schechter M; Soto-Ramirez L; Carosi G; Smaill F; Jordan JC; Pharo CE; Thomas NE; Steel HM
    Curr Med Res Opin; 2004 Jul; 20(7):1115-23. PubMed ID: 15265256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir.
    Kosel BW; Aweeka FT; Benowitz NL; Shade SB; Hilton JF; Lizak PS; Abrams DI
    AIDS; 2002 Mar; 16(4):543-50. PubMed ID: 11872997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients.
    Hayashi S; Jayesekera D; Jayewardene A; Shah A; Thevanayagam L; Aweeka F
    J Clin Pharmacol; 1999 Oct; 39(10):1085-93. PubMed ID: 10516944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.
    Brendel K; Legrand M; Taburet AM; Baron G; Goujard C; Mentré F;
    Fundam Clin Pharmacol; 2005 Jun; 19(3):373-83. PubMed ID: 15910662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics.
    Hennessy M; Clarke S; Spiers JP; Mulcahy F; Kelleher D; Meadon E; Maher B; Bergin C; Khoo S; Tjia J; Hoggard P; Back D; Barry M
    Antivir Ther; 2003 Jun; 8(3):191-8. PubMed ID: 12924535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire.
    Danel C; Moh R; Peytavin G; Anzian A; Minga A; Gomis OB; Seri B; Nzunettu G; Gabillard D; Salamon R; Bissagnene E; Anglaret X
    AIDS Res Hum Retroviruses; 2007 Jan; 23(1):62-6. PubMed ID: 17263634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropharmacokinetic evaluation of lactoferrin-treated indinavir-loaded nanoemulsions: remarkable brain delivery enhancement.
    Karami Z; Saghatchi Zanjani MR; Rezaee S; Rostamizadeh K; Hamidi M
    Drug Dev Ind Pharm; 2019 May; 45(5):736-744. PubMed ID: 30640551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers.
    Saah AJ; Winchell GA; Nessly ML; Seniuk MA; Rhodes RR; Deutsch PJ
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2710-5. PubMed ID: 11557459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy.
    Verstuyft C; Marcellin F; Morand-Joubert L; Launay O; Brendel K; Mentré F; Peytavin G; Gérard L; Becquemont L; Aboulker JP;
    AIDS; 2005 Dec; 19(18):2127-31. PubMed ID: 16284462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
    Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
    Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.